Skip to main content
Signal8

Schrodinger, Inc. (SDGR) Form 10-Q — Nov 4, 2026

$SDGRForm 10-QFiled Nov 4, 2026, 4:08 PM ET0001490978-26-000076Original filing

Schrödinger filed its Q3 2026 10-Q showing quarterly revenue of $64.5 million, up 18.7% year-over-year, with drug discovery revenue nearly doubling to $24.2 million. Net loss was $37.7 million in the quarter and $91.8 million for the nine months, an improvement from $135.8 million a year earlier, with Q3 EPS of $(0.50). The company ended the quarter with $373.4 million in cash, cash equivalents, restricted cash and marketable securities, bolstered by roughly $57.2 million received from Eli Lilly's acquisition of co-founded Ajax Therapeutics.

Key figures

Revenue
181967000
Revenue Yoy
Q3 revenue +18.7% YoY ($64.5M vs $54.3M); nine-month revenue $182.0M vs $168.6M
Total Assets
611940000
Cash Position
373378000
Q3 2026 revenue
64491000
Ajax liquidity payment
57200000
Atm capacity remaining
241132000
Software revenue 9m 2026
106257000
Norse remaining milestones
1424000000
Operating cash flow 9m 2025
29992000
Drug discovery revenue 9m 2026
70052000
Remaining performance obligations
186670000

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.